753 related articles for article (PubMed ID: 16162884)
1. Beta-thalassemia.
Rund D; Rachmilewitz E
N Engl J Med; 2005 Sep; 353(11):1135-46. PubMed ID: 16162884
[No Abstract] [Full Text] [Related]
2. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
3. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
4. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
Efthimia V; Neokleous N; Agapidou A; Economou M; Vetsiou E; Teli A; Perifanis V
Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
[No Abstract] [Full Text] [Related]
5. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
[TBL] [Abstract][Full Text] [Related]
6. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
7. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
9. Deferiprone-induced seizures in a patient with β-thalassemia major.
Mallat NS; Beydoun A; Musallam KM; Koussa S; Taher AT
Blood Cells Mol Dis; 2013 Aug; 51(2):94-5. PubMed ID: 23587452
[No Abstract] [Full Text] [Related]
10. Retinal abnormalities in β-thalassemia major.
Bhoiwala DL; Dunaief JL
Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
Galanello R
Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation therapy for transfusional iron overload: a swift evolution.
Musallam KM; Taher AT
Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
[TBL] [Abstract][Full Text] [Related]
13. Current approach to iron chelation in children.
Aydinok Y; Kattamis A; Viprakasit V
Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
[TBL] [Abstract][Full Text] [Related]
14. Oral iron chelation therapy for thalassaemia: an uncertain scene.
Pippard MJ; Weatherall DJ
Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
[No Abstract] [Full Text] [Related]
15. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
[No Abstract] [Full Text] [Related]
16. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
Wu KH; Chang JG; Ho YJ; Wu SF; Peng CT
Hemoglobin; 2006; 30(2):251-6. PubMed ID: 16798650
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Wu KH; Chang JS; Tsai CH; Peng CT
Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
[TBL] [Abstract][Full Text] [Related]
18. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
Kuo HT; Tsai MY; Peng CT; Wu KH
Hemoglobin; 2006; 30(2):291-9. PubMed ID: 16798654
[TBL] [Abstract][Full Text] [Related]
19. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Voskaridou E; Christoulas D; Terpos E
Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
[No Abstract] [Full Text] [Related]
20. [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
Martín M; Estornell J; Orero M; Pérez JL; Ridocci F; Martínez V
Rev Esp Cardiol; 2006 Jan; 59(1):75-7. PubMed ID: 16434009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]